Paradromics accepted to FDA regulatory accelerator program and announces new patient registry
Paradromics Inc., a leading developer of brain-computer interfaces (BCI), announced its acceptance into the U.S. Food and Drug Administration's newest program for innovative devices, the Total Product Life Cycle Advisory Program.